Sign in
Taking people in United StatesPhase 3

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Key facts

Who runs it
AstraZeneca
Where
Amarillo, Annapolis, Atlanta, Baton Rouge, Birmingham, Boise, Bradenton, Brooklyn, Buffalo, Chapel Hill, Charlottesville, Chicago, Chula Vista, Cleveland, Colorado Springs, Columbia, Columbus, Corvallis, Dallas, Denver, Detroit, Durham, El Paso, Elmhurst, Evanston, Fort Wayne, Fresno, Gainesville, Green Bay, Greenville, Houston, Iowa City, Jacksonville, Kansas City, La Mesa, Lakeland, Los Angeles, Louisville, Miami, Milwaukee, Mobile, New Orleans, New York, Newport Beach, Oklahoma City, Philadelphia, Phoenix, Pittsburgh, Portland, Potsdam, Providence, Royal Oak, Saint Paul, Salt Lake City, Shreveport, Silver Spring, Sioux Falls, South Pasadena, Springfield, St Louis, St. Petersburg, Tampa, Toledo, Torrance, Tucson, Washington D.C., Winston-Salem, and Worcester, United StatesSee the 68 sitesAlso in 38 other countries, 308 sites
Status
Recruiting
Phase
Phase 3
People taking part
3,527 people, planned
Started
13 Dec 2022
Expected to end
4 Nov 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Tozorakimab
  • Placebo
Record updated
30 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Adult participants ≥ 18 years old at the time of signing the informed consent form
  • Patients hospitalised with viral lung infection
  • Hypoxaemia requiring treatment with supplemental O2; Hypoxaemia is defined as:; SpO2 ≤ 90% OR; SpO2 ≤ 92% AND one or both of the following:; Radiographic infiltrates by CXR/CT compatible with viral lung infection per investigator judgement; Use of accessory muscles of respiration or RR (respiratory rate) > 22
  • Patient remains hypoxaemic at randomisation requiring treatment with supplemental oxygen

Who cannot take part

  • Known fungal or parasitic lung infection, aspiration lung infection, lung abscess, or evidence of septic shock. Bacterial co-infection is allowed, unless, in the opinion of the investigator, bacterial infection defines the severity of the participant's condition
  • Hypoxaemia caused primarily by extrapulmonary insult or by lung injury of non-infective aetiology
  • Ongoing IMV/ECMO at randomisation

Where in United States

Also in 38 other countries, 308 sites

  • Amarillo, TexasHospital not named in the registryNot yet recruiting
  • Annapolis, MarylandHospital not named in the registryTaking people
  • Atlanta, GeorgiaHospital not named in the registryNo longer taking part
  • Baton Rouge, LouisianaHospital not named in the registryTaking people
  • Birmingham, AlabamaHospital not named in the registryNot yet recruiting
  • Boise, IdahoHospital not named in the registryTaking people
  • Bradenton, FloridaHospital not named in the registryNo longer taking part
  • Brooklyn, New YorkHospital not named in the registryNo longer taking part
  • Buffalo, New YorkHospital not named in the registryNot yet recruiting
  • Chapel Hill, North CarolinaHospital not named in the registryNo longer taking part
  • Charlottesville, VirginiaHospital not named in the registryTaking people
  • Chicago, IllinoisHospital not named in the registryNo longer taking part
  • Chula Vista, CaliforniaHospital not named in the registryNo longer taking part
  • Cleveland, OhioHospital not named in the registryNo longer taking part
  • Colorado Springs, ColoradoHospital not named in the registryTaking people
  • Columbia, MissouriHospital not named in the registryNo longer taking part
  • Columbus, OhioHospital not named in the registryTaking people
  • Corvallis, OregonHospital not named in the registryNo longer taking part
  • Dallas, TexasHospital not named in the registryNo longer taking part
  • Denver, ColoradoHospital not named in the registryNo longer taking part
  • Detroit, MichiganHospital not named in the registryTaking people
  • Durham, North CarolinaHospital not named in the registryNot yet recruiting
  • El Paso, TexasHospital not named in the registryTaking people
  • Elmhurst, IllinoisHospital not named in the registryNo longer taking part
  • Evanston, IllinoisHospital not named in the registryTaking people
  • Fort Wayne, IndianaHospital not named in the registryNo longer taking part
  • Fresno, CaliforniaHospital not named in the registryTaking people
  • Gainesville, FloridaHospital not named in the registryTaking people
  • Green Bay, WisconsinHospital not named in the registryNo longer taking part
  • Greenville, South CarolinaHospital not named in the registryNo longer taking part
  • Houston, TexasHospital not named in the registryNo longer taking part
  • Iowa City, IowaHospital not named in the registryNo longer taking part
  • Jacksonville, FloridaHospital not named in the registryTaking people
  • Kansas City, MissouriHospital not named in the registryNo longer taking part
  • La Mesa, CaliforniaHospital not named in the registryNo longer taking part
  • Lakeland, FloridaHospital not named in the registryTaking people
  • Los Angeles, CaliforniaHospital not named in the registryNo longer taking part
  • Louisville, KentuckyHospital not named in the registryTaking people
  • Miami, FloridaHospital not named in the registryNo longer taking part
  • Milwaukee, WisconsinHospital not named in the registryNo longer taking part
  • Mobile, AlabamaHospital not named in the registryTaking people
  • New Orleans, LouisianaHospital not named in the registryNo longer taking part
  • New YorkHospital not named in the registryNo longer taking part
  • Newport Beach, CaliforniaHospital not named in the registryTaking people
  • Oklahoma City, OklahomaHospital not named in the registryTaking people
  • Philadelphia, PennsylvaniaHospital not named in the registryNo longer taking part
  • Phoenix, ArizonaHospital not named in the registryNo longer taking part
  • Pittsburgh, PennsylvaniaHospital not named in the registryNot yet recruiting
  • Portland, OregonHospital not named in the registryNo longer taking part
  • Potsdam, New YorkHospital not named in the registryNo longer taking part
  • Providence, Rhode IslandHospital not named in the registryNo longer taking part
  • Royal Oak, MichiganHospital not named in the registryTaking people
  • Saint Paul, MinnesotaHospital not named in the registryTaking people
  • Salt Lake City, UtahHospital not named in the registryTaking people
  • Shreveport, LouisianaHospital not named in the registryNo longer taking part
  • Silver Spring, MarylandHospital not named in the registryNo longer taking part
  • Sioux Falls, South DakotaHospital not named in the registryNo longer taking part
  • South Pasadena, CaliforniaHospital not named in the registryNo longer taking part
  • Springfield, MissouriHospital not named in the registryNo longer taking part
  • St Louis, MissouriHospital not named in the registryTaking people
  • St. Petersburg, FloridaHospital not named in the registryNo longer taking part
  • Tampa, FloridaHospital not named in the registryTaking people
  • Toledo, OhioHospital not named in the registryTaking people
  • Torrance, CaliforniaHospital not named in the registryTaking people
  • Tucson, ArizonaHospital not named in the registryTaking people
  • Washington D.C., District of ColumbiaHospital not named in the registryTaking people
  • Winston-Salem, North CarolinaHospital not named in the registryTaking people
  • Worcester, MassachusettsHospital not named in the registryNo longer taking part

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.

The 2 groups in the trial

  • TozorakimabTreatment being tested

    Approximately 2870 participants will be randomized in a 1:1 ratio. Arm 1 (n=approximately 1435) will receive a single dose of tozorakimab.

  • PlaceboPlacebo, for comparison

    Approximately 2870 participants will be randomized in a 1:1 ratio. Arm 2 (n=approximately 1435) will receive matching placebo.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Record updated
30 October 2026